Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine followed by CIA (DAC-CIA) in Acute Leukemia
NCT01794702Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose of Clofarabine and Objective Response Rate at 56 days. Started Feb 2013; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01794702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794702.